Shukra Pharmaceuticals Ltd
Allottment of Preference Shares
FUNDRAISE
▲ Positive Development
LOW RISK
📅 Filed on BSE: 02 Sep 2026, 06:49 PM IST · BSE ID: 2618a418-5910-439d-825a-745c49a0b106
View Original BSE Filing (PDF)
💡
In Simple Terms
Shukra Pharmaceuticals converted 11.73 lakh warrants into shares, raising over Rs. 3.12 Crore and increasing its capital.
🤖 AI Summary
- Shukra Pharmaceuticals allotted 11,73,000 equity shares upon conversion of warrants.
- The conversion raised Rs. 3,12,83,910/- through the exercise price payment.
- Allotment made to Navkar Surgical Gujarat Limited, a promoter entity.
- Company's paid-up equity capital increased to Rs. 44,07,87,440/-.
- 17,35,000 warrants remain outstanding for future conversion.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares Allotted
11,73,000
Face Value per Share
Re.1/-
Amount Raised on Conversion
Rs.3,12,83,910/-
Exercise Price Paid
Rs.26.67/- per share warrant
Total Paid-up Equity Capital (Post-Allotment)
Rs.44,07,87,440/-
Total Outstanding Warrants
17,35,000
Original Warrant Allotment Date
January 28, 2026
🏢 How This Affects the Company
The company received Rs. 3,12,83,910/- in cash upon conversion, increasing its equity share capital and strengthening its balance sheet.
👥 What This Means For Shareholders
✅
Action Required
No action is required from existing shareholders for this allotment.
👤
Who Is Affected
All existing equity shareholders are affected by the increase in the total number of equity shares.
🔍
Management Signal
Management is executing on its fundraising plans via warrant conversions.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Future conversion of the remaining 17,35,000 warrants.
Company's next quarterly financial results.
Management commentary on utilization of funds raised.
LOW RISK
Routine capital raising event with clear terms and identified allottee.
💡 Investor Takeaway
Shukra Pharmaceuticals allotted 11,73,000 shares on warrant conversion, raising Rs. 3,12,83,910/-. Paid-up capital is now Rs. 44,07,87,440/-.
⚖️ Strengths & Concerns
✅ Positives
- Successful conversion of 11,73,000 warrants, bringing in Rs. 3.12 Crore in cash.
- 17,35,000 warrants still outstanding, providing potential for future capital inflow.
⚠️ Concerns
- Remaining 17,35,000 warrants require further exercise price payment within 18 months.
- Dilution of existing shareholder equity due to the issuance of new shares.
📅 Company Track Record
In June 2026, Shukra Pharmaceuticals planned a Rs. 16.51 Cr preferential issue via warrants. In May 2026, promoters were allotted 17.35 lakh shares, raising Rs. 4.42 Cr.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
How many equity shares did Shukra Pharmaceuticals allot on conversion of warrants?
Shukra Pharmaceuticals allotted 11,73,000 fully paid-up equity shares of Re.1/- each upon conversion of warrants.
What amount did Shukra Pharmaceuticals raise from this warrant conversion?
The company raised Rs. 3,12,83,910/- (Rupees Three Crore Twelve Lakh Eighty-Three Thousand Nine Hundred Ten Only) from the conversion.
Who was the allottee for these converted equity shares?
The allotment was made to Navkar Surgical Gujarat Limited, a promoter entity.
What is the current total paid-up equity capital of Shukra Pharmaceuticals?
Following the allotment, the company's paid-up equity capital increased to Rs. 44,07,87,440/-.
How many warrants are still outstanding for conversion?
There are 17,35,000 total warrants outstanding for conversion into equity shares.
Questions based on this BSE filing only. For information purposes.